Skip to main content
main-content

27.05.2022 | COVID-19 | Original Article

Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial

verfasst von: Biju George, Mahesh Moorthy, Uday Kulkarni, Sushil Selvarajan, Priscilla Rupali, D. J. Christopher, T. Balamugesh, Winsley Rose, Kavitha M. Lakshmi, Anup J. Devasia, N. A. Fouzia, Anu Korula, Sharon Lionel, Aby Abraham, Vikram Mathews

Erschienen in: Indian Journal of Hematology and Blood Transfusion

Einloggen, um Zugang zu erhalten

Abstract

Repurposed drugs may reduce morbidity and mortality in patients with hematological disorders who develop COVID-19 illness. 112 patients with predominantly hematological illnesses were randomized to receive standard of care, ivermectin 12 mg [Iv 12] or 24 mg [Iv24] for asymptomatic, mild, or moderate COVID 19 illness. Serial respiratory samples for rRT-PCR samples were sent on Day 3, 5 and 7. rRT-PCR negativity and ≥ 2 log10 reduction in viral loads on day 3, 5 and 7 were similar between the 3 treatment groups across all disease categories. Symptom progression occurred in 26 patients [21.6%] with no difference across 3 treatment groups. Twenty-two patients [18.3%] have expired while 98 [81.7%] survived. Survival rates were similar across treatment groups [controls—80.5%, Iv12—77.5%, Iv24—87.2% respectively]. Overall, poorer survival was seen with moderate illness compared to others [51.6% vs 92.1%; p = 0.000] and was the only significant risk factor identified on multivariate analysis. In this Phase II randomised trial, single dose of 12 or 24 mg of ivermectin did not reduce viral loads, prevent symptom progression, or reduce mortality in patients with predominantly haematological illnesses who develop mild to moderate COVID 19 illness.
Literatur
1.
Zurück zum Zitat Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR et al (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 20(395):1907–1918 CrossRef Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR et al (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 20(395):1907–1918 CrossRef
2.
Zurück zum Zitat Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335–337 CrossRef Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335–337 CrossRef
3.
Zurück zum Zitat Lee LYW, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA et al (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 20(395):1907–1926 Lee LYW, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA et al (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 20(395):1907–1926
4.
Zurück zum Zitat Passamonti F, Cattaneo C, Arcaini L et al (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy: a retrospective multicenter cohort study. Lancet Haematol 7(10):e737–e745 CrossRef Passamonti F, Cattaneo C, Arcaini L et al (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy: a retrospective multicenter cohort study. Lancet Haematol 7(10):e737–e745 CrossRef
6.
Zurück zum Zitat Zou L, Ruan F, Huang M et al (2020) SARS-CoV-2 Viral Load in Upper Respiratory Specimens of infected patients. NEJM 382(12):1177–1179 CrossRef Zou L, Ruan F, Huang M et al (2020) SARS-CoV-2 Viral Load in Upper Respiratory Specimens of infected patients. NEJM 382(12):1177–1179 CrossRef
7.
Zurück zum Zitat Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M et al (2020) Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 20(6):656–657 CrossRef Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M et al (2020) Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 20(6):656–657 CrossRef
8.
Zurück zum Zitat Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang F et al (2020) Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med 201(9):1150–1152 CrossRef Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang F et al (2020) Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med 201(9):1150–1152 CrossRef
9.
Zurück zum Zitat Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062 CrossRef Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062 CrossRef
10.
Zurück zum Zitat Samaha AA, Mouawia H, Fawaz M et al (2021) Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS—Cov 2 infected subjects: a pilot clinical trial in Lebanon. Viruses 13(6):989 CrossRef Samaha AA, Mouawia H, Fawaz M et al (2021) Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS—Cov 2 infected subjects: a pilot clinical trial in Lebanon. Viruses 13(6):989 CrossRef
13.
Zurück zum Zitat Lopez-Medina E, Lopez P, Hurtado IC et al (2021) Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA 325(14):1426–1435 CrossRef Lopez-Medina E, Lopez P, Hurtado IC et al (2021) Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA 325(14):1426–1435 CrossRef
17.
Zurück zum Zitat Biernat MM, Kolasinska A, Kwiatkowski J et al (2021) Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID 19. Viruses 13(3):436 CrossRef Biernat MM, Kolasinska A, Kwiatkowski J et al (2021) Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID 19. Viruses 13(3):436 CrossRef
18.
Zurück zum Zitat Hueso T, Pouderoux C, Pere H et al (2020) Convalescent plasma therapy for B cell depleted patients with protracted COVID-19. Blood 136(20):2290–2295 CrossRef Hueso T, Pouderoux C, Pere H et al (2020) Convalescent plasma therapy for B cell depleted patients with protracted COVID-19. Blood 136(20):2290–2295 CrossRef
19.
Zurück zum Zitat Jeyaraman P, Agrawal N, Bhargava R et al (2021) Convalescent plasma therapy for severe COVID 19 in patients with hematological malignancies. Transfus Apher Sci 60:103075 CrossRef Jeyaraman P, Agrawal N, Bhargava R et al (2021) Convalescent plasma therapy for severe COVID 19 in patients with hematological malignancies. Transfus Apher Sci 60:103075 CrossRef
20.
Zurück zum Zitat Villegas C, Poza M, Talayero P et al (2020) IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-Cov-2 infection. Ann Hematol 99(12):2953–2956 CrossRef Villegas C, Poza M, Talayero P et al (2020) IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-Cov-2 infection. Ann Hematol 99(12):2953–2956 CrossRef
21.
Zurück zum Zitat Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 178:104787 CrossRef Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 178:104787 CrossRef
22.
Zurück zum Zitat Ahmed S, Karim MM, Ross AG et al (2021) A five-day course of ivermectin for the treatment of COVID 19 may reduce the duration of illness. Int J Infect Dis 103:214–216 CrossRef Ahmed S, Karim MM, Ross AG et al (2021) A five-day course of ivermectin for the treatment of COVID 19 may reduce the duration of illness. Int J Infect Dis 103:214–216 CrossRef
23.
Zurück zum Zitat Okamus N, Nemirturk N, Cetinkaya RA et al (2021) Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID 19 patients. BMC Infect Dis 21(1):411 CrossRef Okamus N, Nemirturk N, Cetinkaya RA et al (2021) Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID 19 patients. BMC Infect Dis 21(1):411 CrossRef
Metadaten
Titel
Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial
verfasst von
Biju George
Mahesh Moorthy
Uday Kulkarni
Sushil Selvarajan
Priscilla Rupali
D. J. Christopher
T. Balamugesh
Winsley Rose
Kavitha M. Lakshmi
Anup J. Devasia
N. A. Fouzia
Anu Korula
Sharon Lionel
Aby Abraham
Vikram Mathews
Publikationsdatum
27.05.2022
Verlag
Springer India
Schlagwort
COVID-19
Erschienen in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-022-01546-w

Corona-Update

Die aktuelle Entwicklung im Überblick: Nachrichten, Webinare, Übersichtsarbeiten.